CompletedPhase 4

Vitamin k1 and Its Relation to Vascular Calcification in Hemodialysis Patients

Egypt120 participantsStarted 2018-01-01

Plain-language summary

Vascular calcification (VC) represents one of the major complications associated with progressive renal impairment. Matrix Gla-protein (MGP) is a vitamin K-dependent protein that acts as a powerful inhibitor of vascular calcification. Despite this fact, it remains unknown whether supplementation with vitamin K can lead to reduction or reversal of vascular and heart valve calcification. Our study aims primarily to investigate the effect of intravenous vitamin K1 three times weekly for a total duration of 6 months on the serum levels of dephosphorylated-uncarboxylated MGP (dp-ucMGP) as well as aortic calcification score and severity of aortic and mitral valve lesions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females ≥18 years of age, * Not less than 6 months on HD, * High level of serum dephosphorylated uc-MGP * Signed informed consent, Exclusion Criteria: * Patients with normal level of dp-ucMGP * History of thrombosis, * Intake of vitamin K antagonists (warfarin) at baseline or in the 3 months prior to baseline, * Inflammatory bowel disease, * Liver dysfunction,

What they're measuring

Effect of vitamin k1 supplementation on vascular calcification

Timeframe: 6 months

Trial details

NCT IDNCT05060809

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-07-30

View on ClinicalTrials.gov More Vascular Calcification trials